{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Nakajima A"],"pubmed_abstract":["<h4>Objective</h4>An interim analysis of postmarketing surveillance reported the safety and efficacy of elobixibat, a laxative medication that inhibits the ileal bile acid transporter, at 4 weeks in approximately 1000 patients with chronic constipation in Japan. However, its long-term safety and efficacy in elderly patients remain unclear. This study aimed to conclude and report the final analysis of postmarketing surveillance, including 52-week safety and efficacy profiles in a clinical practice setting, using approximately 3000 patients.<h4>Methods</h4>The overall survey period spanned from June 2018 to May 2022. Observation periods were set at 4 weeks (4-week treatment period) and 52 weeks (52-week treatment period). Adverse drug reactions and efficacy outcomes, including defecation fre"],"journal":["SAGE open medicine"],"pagination":["20503121251321659"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11863239"],"repository":["biostudies-literature"],"pubmed_title":["A multicenter, postmarketing surveillance of elobixibat in patients with chronic constipation in Japan: A final analysis report."],"pmcid":["PMC11863239"],"pubmed_authors":["Shimada Y","Umeyama M","Nakajima A","Arai Y","Higashikawa M"],"additional_accession":[]},"is_claimable":false,"name":"A multicenter, postmarketing surveillance of elobixibat in patients with chronic constipation in Japan: A final analysis report.","description":"<h4>Objective</h4>An interim analysis of postmarketing surveillance reported the safety and efficacy of elobixibat, a laxative medication that inhibits the ileal bile acid transporter, at 4 weeks in approximately 1000 patients with chronic constipation in Japan. However, its long-term safety and efficacy in elderly patients remain unclear. This study aimed to conclude and report the final analysis of postmarketing surveillance, including 52-week safety and efficacy profiles in a clinical practice setting, using approximately 3000 patients.<h4>Methods</h4>The overall survey period spanned from June 2018 to May 2022. Observation periods were set at 4 weeks (4-week treatment period) and 52 weeks (52-week treatment period). Adverse drug reactions and efficacy outcomes, including defecation fre","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2025-04-03T23:44:13.29Z","creation":"2025-04-03T23:44:13.29Z"},"accession":"S-EPMC11863239","cross_references":{"pubmed":["40012762"],"doi":["10.1177/20503121251321659"]}}